Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
A handful of financial components go into the FFER. Below are the relative values for VCEL. You can read more here.
Price/Sales | very expensive |
Price/Earnings | very cheap |
Price/Operating Income | very cheap |
Price/Book | very expensive |
Debt Ratio | very low |
Dividend Yield | very low |
Sales growth (1y) | high |
Sales growth (3y) | very high |
Earnings growth (1y) | very low |
Earnings growth (3y) | average |